Haku

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds

QR-koodi
Finna-arvio
Lisää ensimmäinen arvostelu. Kaikki arvostelut ovat julkisia.

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds

https://trepo.tuni.fi/handle/10024/151073
http://www.urn.fi/URN:NBN:fi:tuni-202309088041
piad015.pdf (Tampereen yliopisto - Trepo)
Artikkeli
C4591007 Clinical Trial Group ; Simões, Eric A.F ; Klein, Nicola P. ; Sabharwal, Charu ; Gurtman, Alejandra ; Kitchin, Nicholas ; Ukkonen, Benita ; Korbal, Piotr ; Zou, Jing ; Xie, Xuping ; Sarwar, Uzma N. ; Xu, Xia ; Lockhart, Stephen ; Cunliffe, Luke ; Lu, Claire ; Ma, Hua ; Swanson, Kena A. ; Koury, Kenneth ; Shi, Pei Yong ; Cooper, David ; Türeci, Ozlem ; Jansen, Kathrin U. ; Şahin, Uğur ; Gruber, William C. ; Tampere University ; Clinical Medicine
2023

In this ongoing study, substantially increased ancestral SARSCoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable.

Tallennettuna:
Kommentit (0)
Henkilökuntanäyttö

Aineistosta vastaa

  • Tampereen yliopisto - Trepo